Compare Adaptive Biotechnologies Corp (ADPT) vs GE Vernova Inc (GEV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GE Vernova Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while GE Vernova Inc trades at $1,087.88 (market cap $289.43B). The key difference: GE Vernova Inc is far larger — about 86.9× Adaptive Biotechnologies Corp's market cap, and GE Vernova Inc pays a 0.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GEV | |
|---|---|---|
Market Cap | $3.33B | $289.43B |
Sector | Health | Technology |
52-Week High | $22.37 | $1.17K |
52-Week Low | $10.24 | $530.00 |
Enterprise Value | $3.19B | $282.07B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GE Vernova (GEV) trades at $1,152.04, up 3.5% with strong bullish technical signals and robust fundamentals. The stock shows impressive profitability with 23.81% net margin and 83.23% ROE, though valuations appear elevated with P/E of 33.67. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q2 2026 estimates await. The company benefits from AI infrastructure demand, with gas turbines powering data centers driving growth.
Outlook remains positive given AI-driven power infrastructure demand and raised 2026 guidance, but premium valuation and execution risks warrant caution. Analyst consensus strongly favors buying with $1,220 price target, representing 6% upside. Key risks include valuation sensitivity and competitive pressures in energy transition markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
